A multi-center, phase I/II study of sequential epigenetic and immune targeting in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. (SEPION)  

Romidepsin (Istodax®), Azacitidin (Vidaza®), nab-Paclitaxel (Abraxane®), Gemcitabin, Durvalumab (Imfinzi®), Lenalidomid (Revlimid®)

Status: Rekrutierung beendet

Klinische Settings

Beteiligte

Identifier

Links

Kontakt